Owlet Inc (OWLT) — Customer relationships shaping a narrow, hardware-driven growth path

Owlet monetizes by selling infant health hardware—chiefly the Owlet Dream/Smart Sock family, Owlet Cam and BabySat—and by layering subscription services for app features and monitoring; the business combines hardware sales (the majority of revenue) with recurring subscription elements and an expanding push into insurance-supported distribution through durable medical equipment (DME) partners. For investors, the critical facts are concentration in a hardware-led revenue mix, rising channel diversification into DME, and material customer concentration that amplifies execution risk. Explore more company and counterparty signals at https://nullexposure.com/.

How Owlet actually makes money and where leverage lives

Owlet’s operating model is straightforward: sell medical-grade and consumer-facing infant monitors, recognize revenue on hardware when control transfers, and capture ongoing revenue through app subscriptions and services for monitoring and analytics. The company reports substantially all revenues from hardware products, and its financials show Revenue TTM of $105.7M and Gross Profit TTM of $53.5M, with profitability still negative on the bottom line and EPS (TTM) of -2.81. Investors should view growth levers through two lenses: product unit growth (hardware shipments) and subscription attachment rates that convert one-time buyers into recurring revenue.

• Distribution is evolving: Owlet sells direct-to-consumer and through retail, and it is actively expanding DME partnerships to put prescription-authorized products like BabySat into insurance-supported channels.
• Revenue concentration is meaningful: sales through the top three customers represented 58% of revenue in the most recent disclosure, creating single-counterparty execution risk.

Learn more about the relationships that matter at https://nullexposure.com/ — we track customer moves and distribution expansion.

The new DME partners — what the press releases say

Owlet’s near-term commercial trajectory is anchored in partnerships that bring BabySat and related pediatric pulse oximeters into insurance-backed distribution. Below I summarize every customer relationship reported in the news results.

PromptCare — FY2026 (marketscreener news)

Owlet announced a strategic DME partnership with PromptCare expected to drive incremental unit shipments as pilot programs scale, signaling an operational push to convert clinical channels into volume for BabySat. (MarketScreener, March 10, 2026).

1 Natural Way — FY2025 (marketscreener news)

Owlet disclosed a DME partnership with 1 Natural Way to expand insurance-supported access for the BabySat infant pulse oximeter, reflecting a broader strategy to place prescription-authorized devices into covered channels. (MarketScreener, March 10, 2026).

PromptCare — FY2025 (marketscreener news)

An earlier mention of PromptCare in FY2025 described a similar strategic DME distribution arrangement to expand availability of the BabySat pediatric pulse oximeter, indicating continuity in channel focus across reporting periods. (MarketScreener, March 10, 2026).

Each of the above items is a discrete press disclosure in public markets coverage; investors should treat them as operational distribution wins that move the company further into payor-supported channels while still maintaining consumer channels.

Operating constraints and what they signal about risk and runway

Owlet’s public filings and disclosures provide explicit operating signals that bear directly on commercial durability and margin dynamics:

• Short-term payment terms are the baseline. The company states payment terms are short-term and do not embed significant financing components, which implies relatively fast cash conversion on hardware sales but less working-capital flexibility.
• Subscription component introduces regulatory and churn risk. Owlet identifies subscription elements that are subject to regulations on cancellations and renewals; this elevates exposure to consumer protection rules and increases the importance of subscription economics.
• Customer mix includes many individuals via DTC. The company continues to sell direct to consumers, and consumer purchases drive a significant portion of hardware volume—this makes unit economics sensitive to marketing ROI and retail channel dynamics.
• Geography: U.S.-centric with global growth pockets. Financial line items show the U.S. as the largest market (dollars cited in filings), while management points to distribution partners in Canada, Australia, the U.K. and the EU as the international expansion vector. Expect domestic performance to dominate near-term results.
• Top-three customer concentration is material. The firm reports that sales through its top three customers accounted for 58% of revenue for a recent year, a structural concentration that increases counterparty risk.
• Primary product mix is hardware-heavy. Management confirms the business generates substantially all revenues from hardware products—this constrains margin expansion unless subscription monetization meaningfully scales.

Those constraints form the framework for downside scenarios: concentrated revenues, hardware-dependent gross margins, regulatory exposure for subscription offerings, and execution risk in migrating to DME channels.

What the channel moves mean for investors

The DME agreements with PromptCare and 1 Natural Way are meaningful for two reasons: they move BabySat toward insurance reimbursement, which reduces the customer out-of-pocket barrier and can expand addressable demand; and they diversify revenue away from retail and pure DTC channels. However, DME rollouts can be operationally intensive and require inventory, billing integration, and payor relationships—areas where Owlet will need scale and controls.

• Positive: Faster adoption through coverage and potential higher average selling price per unit via DME.
• Negative: Execution complexity and potential margin pressure from DME billing and returns; these are intensified when the company already records high customer concentration.

Mid-deck call to action: for portfolio managers tracking OWLT’s customer pivot, detailed monitoring of partner rollouts and shipment cadence is essential — see more documentation and relationship tracking at https://nullexposure.com/.

Investment implications and risk framework

Owlet’s narrative is one of hardware-led revenue plus nascent recurring revenue, with a strategic pivot to DME distribution to accelerate adoption of prescription products. For investors:

• Upside comes from successful DME scale, higher subscription attach rates, and improved unit economics that convert to positive operating leverage.
• Downside is concentrated counterparty exposure, execution risk in DME integration, and margin pressure while hardware sales dominate.

Key financial signals to watch in quarterly updates: unit shipments through DME partners, subscription ARR or attachment rate, revenue concentration trends (top-three customers as a percent of sales), and any changes to payment or warranty terms that affect working capital.

Final read and next steps

Owlet is executing a clear growth playbook: maintain strong consumer sales while industrializing distribution via DME partners to reach payor-backed demand. That creates a binary set of outcomes—either DME becomes a reliable growth channel that reduces customer concentration and extends lifetime revenue per user, or execution difficulty and concentration risks cap upside.

If you are evaluating OWLT exposures, prioritize monitoring partner rollout KPIs and subscription economics. For structured research and ongoing relationship monitoring, visit https://nullexposure.com/ — we aggregate and surface partner disclosures and channel updates that matter for investors.

For immediate access to relationship-level summaries and filings referenced here, see https://nullexposure.com/.